Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment Milestone

Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment Milestone

Publication date: Aug 10, 2019

SALT LAKE CITY, Aug. 09, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain.

In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.

Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain.

Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications.

In the clinical study, Predictive is testing patients who are taking high doses of opioids [≥50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction.

We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases. “

Concepts Keywords
Blood Drug metabolism
Cancer Pharmacogenomic
CEO Paracetamol
Chronic Pain Analgesic
Chronic Pain Syndrome Opioid
Degenerative Disc Disease Regenerative diagnostic products
Drug Metabolism Chronic pain
Endometriosis Osteoarthritis
FDA Endometriosis
Gene Pharmacogenomics
Genetic Medicine
Genetic Predisposition Health
Genome RTT
Intellectual Property Illness
Lumbar Pain Chronic pain
Metabolism Pain
Metabolize Chronic pain syndrome
Milestone Illness therapeutic products
Milligram
Morphine
Opioid
Opioid Addiction
Opioids
Osteoarthritis
OTC PINK
Pain
Pain Medications
Pharmaceutical
Pharmacogenomic
Pharmacogenomics
Predictive Analytics
SALT LAKE CITY
Scoliosis
Society
Test

Semantics

Type Source Name
pathway BSID Metabolism
disease DOID syndrome
disease MESH syndrome
disease DOID endometriosis
disease MESH endometriosis
disease MESH osteoarthritis lumbar
disease MESH chronic pain
gene UNIPROT OTC
disease DOID scoliosis
disease DOID degenerative disc disease
disease MESH development
pathway BSID Release
gene UNIPROT IMPACT
disease MESH scoliosis
disease MESH suffering
disease MESH genetic markers
disease MESH opioid addiction
disease MESH pain thresholds
gene UNIPROT MMP12
drug DRUGBANK Morphine
disease DOID cancer
disease MESH cancer
drug DRUGBANK Tropicamide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *